首页> 外文OA文献 >FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

【2h】

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

机译：FDA批准摘要：Olaparib单药治疗有害种系BRCA-突变的晚期卵巢癌治疗，用三种或更多种化疗进行治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Geoffrey Kim; Gwynn Ison; Amy E. McKee; Hui Zhang; Shenghui Tang; Thomas Gwise; Rajeshwari Sridhara; Eunice Lee; Abraham Tzou; Reena Philip; Haw-Jyh Chiu; Tiffany K. Ricks; Todd Palmby; Anne Marie Russell; Gaetan Ladouceur; Elimika Pfuma; Hongshan Li; Liang Zhao; Qi Liu; Rajesh Venugopal; Amna Ibrahim; Richard Pazdur;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy [J] . Kim Geoffrey, Ison Gwynn, Mckee Amy E., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第19期

机译：FDA批准摘要：使用三行或更多行化学疗法治疗有害生殖系BRCA突变的晚期卵巢癌患者的Olaparib单药治疗
2. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy [J] . Geoffrey Kim, Gwynn Ison, Amy E. McKee, Cancer reviews . 2015,第Nova期

机译：FDA批准摘要：Olaparib单药治疗有害种系BRCA-突变的晚期卵巢癌治疗，用三种或更多种化疗进行治疗
3. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer [J] . Shaily Arora, Rajeshwari Sridhara, Francisca Reyes Turcu, The oncologist . 2021,第1期

机译：FDA批准摘要：Olaparib单疗法或与Bevacizumab组合用于治疗晚期卵巢癌患者
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. A comparative study of quality of life in patients with low-and intermediate-risk prostate cancer treated at a single institution: Stereotactic radiotherapy vs. high dose-rate brachytherapy monotherapy vs. high dose-rate brachytherapy boost [D] . Helou, Joelle. 2017

机译：单一机构治疗的中低危前列腺癌患者生活质量的比较研究：立体定向放疗与高剂量率近距离放射疗法单药疗法与高剂量率近距离放射疗法增强
6. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer [O] . Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, 2021

机译：FDA批准摘要：Olaparib单疗法或与Bevacizumab组合用于治疗晚期卵巢癌的患者
7. 33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial [O] . RT Penson, RV Valencia, D Cibula, 2019

机译：33奥拉帕里布单疗法对（对）种子BRCA突变的（GBRCAM）铂敏感复发卵巢癌（PSR OC）患者（PTS）：III期SOLO3试验

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

著录项

相似文献

相关主题

期刊订阅